Published on
August 4, 2017
- 21:31 GMT
Akaal Pharma Initiates Phase-2 Clinical Trial of Topical AKP-11 for the Treatment of Atopic Dermatitis (Eczema)
AKP-11 demonstrated efficacy, safety and tolerability in Phase-1. AKP-11 offers new potential topical treatment of moderate-to-severe atopic dermatitis. MELBOURNE, VICTORIA, AUSTRALIA , August 4, 2017 /EINPresswire.com/ -- Akaal Pharma Pty Ltd, an …
Distribution channels:
Business & Economy
...